Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

X
Trial Profile

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDI-101150 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Gastric cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Nimbus Therapeutics
  • Most Recent Events

    • 23 May 2024 According to a Nimbus Therapeutics media release, data from the study will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 June 4, 2024 in Chicago, IL.
    • 23 May 2024 Results (n=59,as of March 18, 2024) presented in the Nimbus Therapeutics Media Release.
    • 31 Oct 2023 According to a Nimbus Therapeutics media release, first clinical data from this trial will be presented at the the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top